Acute Myocardial Infarction Clinical Trial
— AV-MDROfficial title:
Abbott Vascular Medical Device Registry
The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use with the aim of confirming safety and performance throughout their expected lifetime, ensuring the continued acceptability of identified risks, detecting emerging risks on the basis of factual evidence, ensuring the continued acceptability of the benefit-risk ratio, and identifying possible systematic misuse or off-label usage such that the intended use can be verified as appropriate.
Status | Recruiting |
Enrollment | 3784 |
Est. completion date | November 2031 |
Est. primary completion date | November 2030 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subject is at least 18 years of age. 2. Subject has a planned procedure, or underwent a procedure, that will use/used one or more Abbott target devices covered in this registry. 3. Subject is willing and able to comply with, or has already completed, the follow-up schedule specified in this protocol. 4. Subject must provide written informed consent prior to any clinical investigation-related data collection or be enrolled under an IRB/EC approved waiver of consent. Exclusion Criteria: 1. Subject has active symptoms and/or a positive test result of COVID-19 or other rapidly spreading novel infectious agent within the prior 2 months of the date of procedure. |
Country | Name | City | State |
---|---|---|---|
Australia | Perth Institute of Vascular Research | Nedlands | WAUS |
Australia | Sir Charles Gairdner Hospital | Nedlands | WAUS |
Austria | Universitätsklinik Graz | Graz | Styria |
Belgium | Onze-Lieve-Vrouwziekenhuis Campus Aalst | Aalst | Eflndrs |
Belgium | AZ Sint-Blasius Ziekenhuis | Dendermonde | Eflndrs |
China | Jinhua Municipal Central Hospital | Jinhua | Zhejian |
China | Ningbo First Hospital | Ningbo | Zhejian |
China | The First Affiliated Hospital of Xi'an Jiaotong University | Xi'an | Shaanxi |
France | CH Chartres | Chartres | Centre |
France | Hôpital Paris Saint-Joseph | Paris | Ile |
Germany | Herz- u. Gefäßzentrum Bad Bevensen | Bad Bevensen | Saxon |
Germany | Cardioangiologisches Centrum am Bethanien Krankenhaus | Frankfurt | Hesse |
Germany | Universitätsklinikum Schleswig-Holstein Campus Kiel | Kiel | Schlesw |
Germany | Universitätsklinikum Leipzig AÖR | Leipzig | Saxony |
Germany | UNIVERSITATSMEDIZIN der Johannes Gutenberg-Universität Mainz | Mainz | Rhinela |
Hungary | Semmelweis University | Budapest | |
Italy | Centro Cardiologico Monzino | Milano | Lombard |
Italy | Ospedale San Raffaele | Milano | Lombard |
Netherlands | St. Antonius Ziekenhuis | Nieuwegein | Utrecht |
Spain | Hospital General Universitario de Alicante | Alicante | Valncia |
Spain | Hospital Universitari Vall d'Hebron | Barcelona | Catalon |
Spain | Hospital Universitario de la Paz | Madrid | |
Switzerland | Kantonsspital Aarau | Aarau | Basel |
Switzerland | Inselspital - University Hospital of Bern | Bern | |
Taiwan | Taichung Veterans General Hospital | Taichung | Mtaiwan |
Taiwan | Chi Mei Hospital | Tainan City | Staiwan |
Taiwan | National Cheng Kung University Hospital | Tainan City | Staiwan |
Taiwan | Cathay General Hospital | Taipei City | Ntaiwan |
United Arab Emirates | Al Qassimi Hospital | Sharjah | |
United States | University Hospital - Univ. of Alabama at Birmingham (UAB) | Birmingham | Alabama |
United States | Northwestern Memorial Hospital | Chicago | Illinois |
United States | Ohio State University | Columbus | Ohio |
United States | Wellmont CVA Heart Institute | Kingsport | Tennessee |
United States | Bryan Heart | Lincoln | Nebraska |
United States | Arkansas Heart Hospital | Little Rock | Arkansas |
United States | Kaiser Permanente Los Angeles Medical Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Abbott Medical Devices |
United States, Australia, Austria, Belgium, China, France, Germany, Hungary, Italy, Netherlands, Spain, Switzerland, Taiwan, United Arab Emirates,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Coronary Stents - Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR) | Composite of all-cause death, MI or target lesion revascularization (TLR) will be assessed among the patients who receive Coronary Stents. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Coronary Stents - Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR) | Composite of all-cause death, MI or target lesion revascularization (TLR) will be assessed among the patients who receive Coronary Stents. | 30 days | |
Primary | Coronary Stents - Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR) | Composite of all-cause death, MI or target lesion revascularization (TLR) will be assessed among the patients who receive Coronary Stents. | 12 months | |
Primary | Peripheral Stents - Number of participants with composite of all-cause death, amputation, and TLR | Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive Peripheral Stents. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Peripheral Stents - Number of participants with composite of all-cause death, amputation, and TLR | Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive Peripheral Stents. | 30 days | |
Primary | Peripheral Stents - Number of participants with composite of all-cause death, amputation, and TLR | Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive Peripheral Stents. | 12 months | |
Primary | Peripheral Stents (Renal Indication) - Number of participants with composite of all-cause death, ipsilateral nephrectomy, Embolic events resulting in kidney damage or TLR | Composite of all-cause death, ipsilateral nephrectomy, Embolic events resulting in kidney damage or TLR will be assessed among the patients who receive Peripheral Stents (Renal Indication). | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Peripheral Stents (Renal Indication) - Number of participants with composite of all-cause death, ipsilateral nephrectomy, Embolic events resulting in kidney damage or TLR | Composite of all-cause death, ipsilateral nephrectomy, Embolic events resulting in kidney damage or TLR will be assessed among the patients who receive Peripheral Stents (Renal Indication). | 30 days | |
Primary | Peripheral Stents (Renal Indication) - Number of participants with composite of TLR | Composite of TLR will be assessed among the patients who receive Peripheral Stents (Renal Indication). | 12 months | |
Primary | Pacing Catheters - Number of participants with composite of potential complications (venous thrombosis, pulmonary emboli, arrhythmias, perforation) | Composite of potential complications (venous thrombosis, pulmonary emboli, arrhythmias, perforation) will be assessed among the patients who receive Pacing Catheters. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Pacing Catheters - Loss of capture (assessed based on physiological parameter-ECG) | Loss of capture (average time of loss of capture across patients) will be assessed among the patients who receive Pacing Catheters. ECG is used to measure whether the pacing device stimulates the heart. Absence of a stimulation is considered a loss of capture. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Vascular Plugs - Number of participants with composite of potential complications (Implant success, occlusion success, migration) | Composite of potential complications including implant success, occlusion success, migration will be assessed among the patients who receive Vascular Plugs. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Vascular Plugs - Number of participants with composite of occlusion success and migration | Composite of occlusion success and migration will be assessed among the patients who receive Vascular Plugs. | 30 days | |
Primary | Fractional flow reserve - Number of participants with composite of vessel dissection, perforation, and thromboembolism | Composite of vessel dissection, perforation, and thromboembolism during procedure will be assessed among the patients who receive Fractional flow reserve (FFR). | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Fractional flow reserve - Number of participants with signal drift (Signal drift between measurements (Pd/Pa** pressure drift >0.03; <0.97 or >1.03) | Signal drift (Signal drift between measurements (Pd/Pa** pressure drift >0.03; <0.97 or >1.03) will be assessed among the patients who receive FFR. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Optical Coherence Tomography Products - Number of participants with Intraprocedural complications (number of dissections =type B, slow flow or no reflow, thrombus, abrupt closure, perforation) | Intraprocedural complications will be assessed among the patients who receive Optical Coherence Tomography (OCT). | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Optical Coherence Tomography Products - Number of participants with Successful crossing and image quality pre-PCI | Successful crossing and image quality pre- PCI will be assessed among the patients who receive OCT. | During procedure - Before the stent is implanted (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Optical Coherence Tomography Products - Number of participants with Successful crossing and image quality post-PCI | Successful crossing and image quality post-PCI will be assessed among the patients who receive OCT. | During procedure - Between 10-30 minutes post-PCI (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Peripheral Dilatation Catheters - Number of participants with Composite of major adverse events | Composite of major adverse events (e.g., distal embolization, dissection, perforation, amputation primary to balloon usage, total occlusion, abrupt closure, renal failure primary to balloon usage will be assessed among the patients who receive Peripheral Dilatation Catheters. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Peripheral Dilatation Catheters - Number of participants with Device success (Successful delivery, Successful inflation, Successful deflation, Successful withdrawal) (assessed based on physiological parameters) | Device success (Successful delivery, Successful inflation, Successful deflation, Successful withdrawal) will be assessed among the patients who receive Peripheral Dilatation Catheters. Device success can be summarized as the successful treatment with the device. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Coronary Guidewires - Number of participants with Composite of major adverse events | Composite of major adverse events (e.g., vessel perforation, dissection, occlusion, embolism) will be assessed among the patients who receive Coronary Guidewires. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Coronary Guidewires - Number of participants with Device success (Successfully placed, Successfully introduce/position diagnostic/interventional device, Successfully reach/cross target lesion) (assessed based on physiological parameters) | Device success (Successfully placed, Successfully introduce/position diagnostic/interventional device, Successfully reach/cross target lesion will be assessed among the patients who receive Coronary Guidewires. Device success can be summarized as the successful treatment with the device. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Peripheral Guidewires - Number of participants with Composite of major adverse events | Composite of major adverse events (e.g., vessel perforation, dissection, occlusion, embolism) will be assessed among the patients who receive Peripheral Guidewires. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Peripheral Guidewires - Number of participants with Device success (Successfully placed, Successfully introduce/position diagnostic/interventional device, Successfully reach/cross target lesion) (assessed based on physiological parameters) | Device success (Successfully placed, Successfully introduce/position diagnostic/interventional device, Successfully reach/cross target lesion will be assessed among the patients who receive Peripheral Guidewires. Device success can be summarized as the successful treatment with the device. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Coronary Dilatation Catheters - Number of participants with Composite of major adverse events | Composite of major adverse events (e.g., distal embolization, dissection, perforation, amputation primary to balloon usage, total occlusion, abrupt closure, renal failure primary to balloon usage will be assessed among the patients who receive Coronary Dilatation Catheters. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Coronary Dilatation Catheters - Number of participants with Device success (Successful delivery, Successful inflation, Successful deflation, Successful withdrawal) (assessed based on physiological parameters) | Device success (Successful delivery, Successful inflation, Successful deflation, Successful withdrawal) will be assessed among the patients who receive Coronary Dilatation Catheters. Device success can be summarized as the successful treatment with the device. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Vessel Closure Devices - Number of participants with Composite of access complications | Composite of access complications (e.g., hematoma, stenosis/occlusion, infection, access site bleeding) will be assessed among the patients who receive Vessel Closure Devices. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Vessel Closure Devices - Number of participants with Successful hemostasis Major and minor bleeding | Successful hemostasis Major and minor bleeding will be assessed among the patients who receive Vessel Closure Devices. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Vessel Compression Devices - Number of participants with Major and minor bleeding | Major and minor bleeding will be assessed among the patients who receive Vessel Compression Devices. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Vessel Compression Devices - Number of participants with Complications including: pseudoaneurysm, hematoma (>5cm) in diameter, Hb drop>20 g/L, extended compression time >6 hours, blood transfusion required, bleeding requiring surgical procedure | Complications including: pseudoaneurysm requiring treatment, hematoma (>5cm) in diameter, Hb drop>20 g/L, extended compression time >6 hours, blood transfusion required, bleeding requiring surgical procedure will be assessed among the patients who receive Vessel Compression Devices. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Vascular Access Introducers - Incidence of safety issues | Incidence of safety issues (e.g., bleeding, air embolism, hematoma, vessel damage (dissection, perforation, pseudoaneurysm), infection, thrombosis, AV fistula, occlusion, radial artery spasm) will be assessed among the patients who receive Vascular Access Introducers. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) | |
Primary | Vascular Access Introducers - Incidence of performance issues | Incidence of performance issues (e.g., unable to introduce other devices, failure to maintain hemostasis valve integrity, air leakage, bending or kinking of introducer, difficulty inserting/removing the sheath, device breakage detachment or separation, issue with an associated accessory) will be assessed among the patients who receive Vascular Access Introducers. | During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04451967 -
Acute Myocardial Infarction Study in Northeastern China
|
||
Completed |
NCT05974397 -
Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
|
||
Not yet recruiting |
NCT04072081 -
Drug-coated Balloon Versus Drug-eluting Stent in the Treatment of Coronary Artery Lesions in STEMI Patients in De Novo Coronary Lesions
|
N/A | |
Recruiting |
NCT03940443 -
Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
|
||
Recruiting |
NCT03707626 -
Collateral Circulation to LAD and Wellens Sign
|
||
Completed |
NCT02669810 -
EXCELLENT (EXpanded CELL ENdocardiac Transplantation)
|
Phase 2 | |
Not yet recruiting |
NCT04104048 -
Short Term Outcome of Primary Precutaneous Coronary Intervention in Ostial Versus Non Ostial Culprit Proximal Left Anterior Descending Artery Acute Myocardial Infraction
|
||
Active, not recruiting |
NCT02915107 -
The SORT OUT IX STEMI OCT Trial
|
N/A | |
Completed |
NCT02896543 -
The Relationship of Change of Dendritic Cells Fractalkine and P-selectin Patients With Acute Myocardial Infarction
|
N/A | |
Completed |
NCT02531165 -
Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
|
N/A | |
Withdrawn |
NCT01901471 -
Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock
|
Phase 2 | |
Completed |
NCT02490969 -
Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19
|
N/A | |
Completed |
NCT02312336 -
A Pilot Study of Transcoronary Myocardial Cooling
|
N/A | |
Recruiting |
NCT02071342 -
Study of ABSORB Stent in Acute Myocardial Infarction
|
N/A | |
Terminated |
NCT01972126 -
MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction
|
N/A | |
Completed |
NCT02070913 -
COOL-AMI EU Case Series Clinical Study
|
||
Withdrawn |
NCT01678339 -
Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients
|
N/A | |
Completed |
NCT01216995 -
Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI)
|
Phase 2 | |
Completed |
NCT01887080 -
Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program
|
N/A | |
Completed |
NCT01673893 -
ClearWay Rx Readmission Registry
|